Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.39−0.61 (-5.08%)
Close on Nov 19, 2026Market cap $225.83MP/E –Yield –
Keros Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Keros Therapeutics's pe ratio was 4.8× on Apr 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 4.8× | −8.4 |
| 2025 | Dec 31, 2025 | 13.2× | – |
See a number that looks wrong?